Payment overview · 2025
General Payments
$3,524.92
145 reported records · 23 companies
Healthcare provider profile · identity verified
Pavan Ahuja, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELKHART, IN · NPI 1578566675
Verified facts
What the public records show
CMS Open Payments records show Pavan Ahuja, M.D. received $3,524.92 in general payments during 2025 across 145 reported records.
Lilly USA, LLC accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $574.70 | 16.3% | 22 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $429.99 | 12.2% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $379.47 | 10.8% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $346.69 | 9.8% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $243.21 | 6.9% | 11 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $200.47 | 5.7% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $199.32 | 5.7% | 15 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $194.30 | 5.5% | 14 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $178.80 | 5.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $124.07 | 3.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $104.45 | 3.0% | 5 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $100.54 | 2.9% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $83.64 | 2.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.04 | 1.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $56.75 | 1.6% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $47.79 | 1.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.33 | 1.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.74 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.29 | 0.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.84 | 0.8% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.91 | 0.7% | 1 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $15.97 | 0.5% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.61 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,506.07 | 144 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $429.99 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $388.27 | 24 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $259.60 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $241.39 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $228.90 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $224.06 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $209.29 | 9 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $200.47 | 9 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $178.80 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $174.37 | 13 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $124.07 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $117.64 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.70 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $105.30 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $101.61 | 8 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $83.64 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $80.49 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $56.75 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $47.79 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.74 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.68 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.95 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 177 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 146 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 255 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 168 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 136 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
133 | 132 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
168 | 122 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
136 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
146 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
255 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 217 |
| Amlodipine Besylate | Amlodipine Besylate | 657 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 159 |
| Losartan Potassium | Losartan Potassium | 546 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 387 | 102 |
| Furosemide | Furosemide | 353 | 111 |
| Simvastatin | Simvastatin | 345 | 90 |
| Lisinopril | Lisinopril | 327 | 77 |
| Metformin Hcl | Metformin Hcl | 297 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 291 | 86 |
| Glimepiride | Glimepiride | 276 | 65 |
| Ozempic | Semaglutide | 255 | 47 |
| Ezetimibe | Ezetimibe | 254 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 68 |
| Omeprazole | Omeprazole | 215 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 56 |
| Trazodone Hcl | Trazodone Hcl | 188 | 55 |
| Jardiance | Empagliflozin | 177 | 41 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 168 | 122 |
| Metformin Hcl Er | Metformin Hcl | 160 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 38 |
| Mounjaro | Tirzepatide | 146 | 18 |
| Gabapentin | Gabapentin | 143 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 63 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 136 | 35 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 133 | 132 |
| Potassium Chloride | Potassium Chloride | 127 | 42 |
| Montelukast Sodium | Montelukast Sodium | 121 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 34 |
| Carvedilol | Carvedilol | 112 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 36 |
| Bupropion Xl | Bupropion Hcl | 109 | 31 |
| Alprazolam | Alprazolam | 105 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 25 |
| Donepezil Hcl | Donepezil Hcl | 92 | suppressed |
| Allopurinol | Allopurinol | 90 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 17 |
| Buspirone Hcl | Buspirone Hcl | 82 | 22 |
| Meloxicam | Meloxicam | 82 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 34 |
| Clonazepam | Clonazepam | 77 | 12 |
| Eliquis | Apixaban | 74 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 20 |
| Famotidine | Famotidine | 69 | 23 |
| Atenolol | Atenolol | 68 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 42 |
| Irbesartan | Irbesartan | 64 | 20 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 63 | 63 |
| Alendronate Sodium | Alendronate Sodium | 63 | 19 |
| Farxiga | Dapagliflozin Propanediol | 63 | 14 |
| Trulicity | Dulaglutide | 63 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 60 | 17 |
| Tramadol Hcl | Tramadol Hcl | 60 | 15 |
| Sertraline Hcl | Sertraline Hcl | 59 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 17 |
| Prednisone | Prednisone | 56 | 42 |
| Fenofibrate | Fenofibrate | 55 | 15 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 16 |
| Diazepam | Diazepam | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 14 |
| Meclizine Hcl | Meclizine Hcl | 43 | 22 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 14 |
| Finasteride | Finasteride | 42 | 13 |
| Azithromycin | Azithromycin | 41 | 36 |
| Klor-Con M20 | Potassium Chloride | 41 | 16 |
| Glipizide | Glipizide | 40 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 13 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | 13 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 15 |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 12 |
| Ramipril | Ramipril | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,524.92 · 145 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AVYCAZ, BREZTRI, CAPLYTA, CARDIOMEMS, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, ELIQUIS, EMBLAVEO, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, INGREZZA, JARDIANCE, Kerendia, MOUNJARO, Monarch Platform, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, VYEPTI, Wegovy, YUPELRI, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error